BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Feb 07, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

IB1001: Phase I data

A double-blind, international, crossover Phase I trial in 32 patients showed that IV IB1001 was non-inferior to Benefix, a commercially available rFIX product from Pfizer Inc. (NYSE:PFE, New York, N.Y.), in the...

Read the full 156 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >